Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Relay Therapeutics (RLAY) Share-based Compensation: 2019-2024

Historic Share-based Compensation for Relay Therapeutics (RLAY) over the last 6 years, with Dec 2024 value amounting to $94.1 million.

  • Relay Therapeutics' Share-based Compensation fell 30.94% to $15.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.0 million, marking a year-over-year decrease of 30.06%. This contributed to the annual value of $94.1 million for FY2024, which is 9.42% up from last year.
  • Relay Therapeutics' Share-based Compensation amounted to $94.1 million in FY2024, which was up 9.42% from $86.0 million recorded in FY2023.
  • Relay Therapeutics' Share-based Compensation's 5-year high stood at $94.1 million during FY2024, with a 5-year trough of $32.0 million in FY2020.
  • In the last 3 years, Relay Therapeutics' Share-based Compensation had a median value of $86.0 million in 2023 and averaged $78.8 million.
  • Data for Relay Therapeutics' Share-based Compensation shows a peak YoY soared of 617.24% (in 2020) over the last 5 years.
  • Yearly analysis of 5 years shows Relay Therapeutics' Share-based Compensation stood at $32.0 million in 2020, then soared by 51.61% to $48.5 million in 2021, then increased by 15.86% to $56.1 million in 2022, then skyrocketed by 53.25% to $86.0 million in 2023, then climbed by 9.42% to $94.1 million in 2024.